HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma

Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma

(2010) L. Paoluzzi et al.   CLINICAL CANCER RESEARCH

OX40 is required for regulatory T cell–mediated control of colitis

(2010) Thibault Griseri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation

(2009) S. Piconese et al.   BLOOD

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors

(2009) Annunziata Gloghini et al.   BRITISH JOURNAL OF HAEMATOLOGY

PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

(2009) S. Bhalla et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right

(2009) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions

(2009) Bérengère Vire et al.   PLoS One

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients

(2008) C. U. Louis et al.   BLOOD

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells

(2008) K. L. Hippen et al.   BLOOD

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

(2008) M. J. Gough et al.   CANCER RESEARCH

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Discovery ofN-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

(2008) Nancy Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

(2008) M. Fournel et al.   MOLECULAR CANCER THERAPEUTICS

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

(2008) Alejandro Villagra et al.   NATURE IMMUNOLOGY